Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Onward-Therapeutics

More Like This

PR Newswire associated0

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

XNK Therapeutics receives EMA scientific recommendation for evencaleucel as an Advanced Therapy Medicinal Product

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

XNK Therapeutics announces poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

PR Newswire associated0

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023

XNK Therapeutics presented two posters at the NK2023 conference in Oslo

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023